- Home
- AIP vs AVIR Comparison
AIP vs AVIR Comparison
Compare AIP & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIP
- AVIR
- Stock Information
- Founded
- AIP 2003
- AVIR 2012
- Country
- AIP United States
- AVIR United States
- Employees
- AIP N/A
- AVIR N/A
- Industry
- AIP Semiconductors
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- AIP Technology
- AVIR Health Care
- Exchange
- AIP Nasdaq
- AVIR Nasdaq
- Market Cap
- AIP 391.5M
- AVIR 290.4M
- IPO Year
- AIP 2021
- AVIR 2020
- Fundamental
- Price
- AIP $10.29
- AVIR $2.97
- Analyst Decision
- AIP Strong Buy
- AVIR Hold
- Analyst Count
- AIP 3
- AVIR 1
- Target Price
- AIP $15.00
- AVIR $6.00
- AVG Volume (30 Days)
- AIP 527.7K
- AVIR 223.7K
- Earning Date
- AIP 11-04-2025
- AVIR 11-06-2025
- Dividend Yield
- AIP N/A
- AVIR N/A
- EPS Growth
- AIP N/A
- AVIR N/A
- EPS
- AIP N/A
- AVIR N/A
- Revenue
- AIP $63,236,000.00
- AVIR N/A
- Revenue This Year
- AIP $19.40
- AVIR N/A
- Revenue Next Year
- AIP $17.91
- AVIR N/A
- P/E Ratio
- AIP N/A
- AVIR N/A
- Revenue Growth
- AIP 18.64
- AVIR N/A
- 52 Week Low
- AIP $5.46
- AVIR $2.46
- 52 Week High
- AIP $14.29
- AVIR $4.10
- Technical
- Relative Strength Index (RSI)
- AIP 62.34
- AVIR 33.48
- Support Level
- AIP $8.42
- AVIR $2.84
- Resistance Level
- AIP $9.00
- AVIR $3.33
- Average True Range (ATR)
- AIP 0.41
- AVIR 0.14
- MACD
- AIP 0.10
- AVIR -0.04
- Stochastic Oscillator
- AIP 98.42
- AVIR 18.98
About AIP Arteris Inc.
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).